Cytori Therapeutics Inc Stock Nasdaq
Stocks
US23283K2042
Biotechnology & Medical Research
| Market Cap | 15.41M 13.43M 12.65M 11.52M 21.6M 1.48B 21.63M 152M 58.4M 752M 57.87M 56.59M 2.43B | P/E 2026 * |
-0.43x | P/E 2027 * | -0.82x |
|---|---|---|---|---|---|
| Enterprise Value | 15.41M 13.43M 12.65M 11.52M 21.6M 1.48B 21.63M 152M 58.4M 752M 57.87M 56.59M 2.43B | EV / Sales 2026 * |
2.67x | EV / Sales 2027 * | 0.8x |
| Free-Float |
98.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| 1 day | +2.09% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 2014-04-01 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 2020-02-05 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 2002-09-30 |
Richard Hawkins
CHM | Chairman | 77 | 2018-01-24 |
| Director/Board Member | 66 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.09% | -17.01% | - | - | 15.41M | |
| +0.59% | +2.73% | +1.48% | +28.74% | 46.28B | |
| +1.17% | +1.62% | +43.73% | +35.54% | 43.85B | |
| +0.86% | -6.41% | +332.27% | +529.82% | 40.93B | |
| +4.19% | +3.38% | +8.28% | +94.80% | 39.89B | |
| +1.11% | +1.80% | +11.52% | +43.15% | 29.5B | |
| +1.61% | +4.82% | +25.30% | +159.17% | 17.09B | |
| +0.54% | -10.15% | - | - | 15.55B | |
| +2.12% | +8.18% | +24.54% | +41.21% | 15.22B | |
| -0.26% | +25.94% | -8.76% | - | 14.05B | |
| Average | +1.42% | +3.97% | +54.80% | +133.20% | 29.15B | |
| Weighted average by Cap. | +1.49% | +2.08% | +68.63% | +141.67% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.77M 5.03M 4.74M 4.32M 8.09M 553M 8.1M 56.78M 21.88M 282M 21.69M 21.2M 909M | 19.14M 16.69M 15.72M 14.31M 26.84M 1.83B 26.87M 188M 72.55M 934M 71.9M 70.31M 3.01B |
| Net income | -32.26M -28.13M -26.49M -24.12M -45.23M -3.09B -45.29M -317M -122M -1.57B -121M -118M -5.08B | -19.05M -16.61M -15.65M -14.25M -26.72M -1.83B -26.75M -187M -72.23M -930M -71.58M -69.99M -3B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
